437 related articles for article (PubMed ID: 35377645)
1. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
Brusa I; Sondo E; Falchi F; Pedemonte N; Roberti M; Cavalli A
J Med Chem; 2022 Apr; 65(7):5212-5243. PubMed ID: 35377645
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
4. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
5. Unravelling druggable signalling networks that control F508del-CFTR proteostasis.
Hegde RN; Parashuraman S; Iorio F; Ciciriello F; Capuani F; Carissimo A; Carrella D; Belcastro V; Subramanian A; Bounti L; Persico M; Carlile G; Galietta L; Thomas DY; Di Bernardo D; Luini A
Elife; 2015 Dec; 4():. PubMed ID: 26701908
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
Strub MD; McCray PB
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
[TBL] [Abstract][Full Text] [Related]
7. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
8. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
9. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
[TBL] [Abstract][Full Text] [Related]
10. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine.
McDonald EF; Meiler J; Plate L
ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207
[TBL] [Abstract][Full Text] [Related]
11. CFTR processing, trafficking and interactions.
Amaral MD; Hutt DM; Tomati V; Botelho HM; Pedemonte N
J Cyst Fibros; 2020 Mar; 19 Suppl 1():S33-S36. PubMed ID: 31680043
[TBL] [Abstract][Full Text] [Related]
12. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
13. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
Amaral MD
Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
[TBL] [Abstract][Full Text] [Related]
14. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
15. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
16. CFTR: folding, misfolding and correcting the ΔF508 conformational defect.
Lukacs GL; Verkman AS
Trends Mol Med; 2012 Feb; 18(2):81-91. PubMed ID: 22138491
[TBL] [Abstract][Full Text] [Related]
17. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
[TBL] [Abstract][Full Text] [Related]
19. Decoding F508del misfolding in cystic fibrosis.
Wang XR; Li C
Biomolecules; 2014 May; 4(2):498-509. PubMed ID: 24970227
[TBL] [Abstract][Full Text] [Related]
20. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.
Tomati V; Caci E; Ferrera L; Pesce E; Sondo E; Cholon DM; Quinney NL; Boyles SE; Armirotti A; Ravazzolo R; Galietta LJ; Gentzsch M; Pedemonte N
JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
